Abstract

Scientific Goals The mission of the HDFCCC Tobacco Control (TO) Program is to reduce the burden of cancer caused by tobacco, locally, in the catchment area, and globally. This mission is advanced through robust Program themes reaching from the molecular level of tobacco-induced disease, to the physical and medical health effects of tobacco, to individual and community tobacco cessation efforts, and to policy and regulatory actions at state, national, and global levels. Theme 1: Biological determinants of tobacco-induced addiction and disease Theme 2: Social and behavioral determinants and interventions for tobacco addiction Theme 3: The tobacco industry as a disease vector and strategies to block it TO Program: Key Metrics Membership (9 departments, 4 schools) 28 Full 14 Associate 14 Cancer-relevant Funding (direct costs as of $9,353,958 05/31/2017) NCI $2,506,751 27% Peer-reviewed $4,804,645 51% Non-peer-reviewed $2,042,562 22% Cancer-relevant Publications (1/2012-7/2017) 492 Inter-programmatic 16 3% Intra-Programmatic 127 26% High-Impact 255 52% Accruals to Clinical Trials (2016) 7350 20 Therapeutic 0 0 Other Interventional 75 4 Non-interventional 7275 16

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA082103-19S2
Application #
9784163
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
19
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118

  Publications

Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Tat, David; Kenfield, Stacey A; Cowan, Janet E et al. (2018) Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE™). Prostate 78:32-39
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49

Showing the most recent 10 out of 192 publications